Discovery, total synthesis, and biological evaluation of tyrcinnamins as antibacterial agents and tyrosinase activators.

Summary

This study discovers and synthetically enables tyrcinnamins, identifying derivative 7a with dual antibacterial and tyrosinase activation activities and an excellent in vitro safety profile. Docking suggests 7a improves l-DOPA engagement at tyrosinase’s active center by competitively occupying surface sites, offering a new scaffold for antibiotics and pigmentation-modulating agents.

Key Findings

• Isolation and total synthesis of tyrcinnamin enabled SAR, leading to derivative 7a with significant antibacterial and tyrosinase activation activities.
• Molecular docking indicates 7a competitively occupies l-DOPA surface binding sites on mushroom tyrosinase, enhancing effective l-DOPA binding at the active center.
• 7a represents a new chemical scaffold with promising safety, relevant to both antibiotic discovery and cosmetic development.

Clinical Implications

While preclinical, tyrosinase activation may translate to therapies for hypopigmentation disorders (e.g., vitiligo), and the antibacterial activity supports anti-infective development for skin applications.

Limitations

• Mechanistic insights are based on docking with mushroom tyrosinase; no human enzyme or in vivo validation presented.
• Lack of animal efficacy and pharmacokinetic data limits immediate translational relevance.

Future Directions

Validate activity against human tyrosinase and clinically relevant pathogens in vivo; optimize pharmacokinetics and topical formulation for dermatologic use.